Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD).
The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several cases of sight-threatening inflammation of blood vessels. Beovu ...
Wie liever geen kunstwerk met een problematische geschiedenis op de kop tikt of zich geen juridische procedures op de hals wil halen, doet er volgens specialisten goed aan spitwerk te doen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback